Seymour de Picciotto
CEO Cellado
Seymour is Founder & CEO of a stealth biotechnology company, where he is building next-generation therapeutics at the intersection of biology and technology. Previously at Moderna, he was a founding member of the Autoimmune and Inflammation Therapeutic Area and led the company’s first mRNA therapeutic for autoimmune disease, mRNA-6231, from concept through Phase I while advancing multiple first-in-class programmes in protein engineering, immunology, and drug development.
Seminars
Wednesday 9th December 2026
Analyzing Emerging Strategies & Future Design Principles for Engineering Extrahepatic Oligonucleotide Delivery
11:00 am
- Analyzing engineering principles underpinning successful extrahepatic oligonucleotide delivery and how different approaches overcome tissue-specific barriers
- Drawing practical lessons from recent publications to identify common themes and emerging best practices
- Compare the strengths and limitations of conjugated and non-conjugated approaches to identify which strategy is best suited to different disease indications and development goals
